17842651047303755420396502188375.jpg

Explain with additional data in simple language

Reading File

analyse_media

Finding Sources

Searching the Web

ALL acute lymphoblastic leukemia BFM-19 protocol MRD treatment induction consolidation maintenance 2024

Reading File

I now have all the information needed to give a thorough, simple explanation. Here is the full breakdown:

Treatment of ALL (Acute Lymphoblastic Leukemia) - Explained Simply

What is ALL?

ALL is a blood cancer where the bone marrow produces too many immature white blood cells (called "blasts"). These abnormal cells flood the blood and crowd out normal cells. Treatment follows a structured, step-by-step plan.

The Treatment Flowchart - Step by Step

STEP 1: Induction Phase (2 cycles)

Think of this as: "Attack and destroy"

Goal: Wipe out as many cancer cells as possible and push the disease into remission (no detectable cancer).

Protocol used: BFM-19 (Berlin-Frankfurt-Munster 2019) - a well-established international treatment protocol, especially used in children and young adults.

Drugs used:

Drug	What it does
Steroids (e.g., Dexamethasone/Prednisone)	Kills lymphoblasts directly; reduces inflammation
Vincristine	Stops cancer cells from dividing (disrupts the mitotic spindle)
Daunorubicin	An anthracycline antibiotic that damages cancer cell DNA
Cyclophosphamide	Alkylating agent - chemically damages cancer cell DNA

Why is L-asparaginase no longer used?

Previously, L-asparaginase was a key drug (it starves cancer cells of the amino acid asparagine)
It is now dropped from many protocols because it causes widespread thrombosis (dangerous blood clots), including cerebral venous sinus thrombosis
Modern protocols (like BFM-19) have replaced or de-escalated its use

Result after induction: About 90% of children and 80-90% of adults achieve complete remission - Goldman-Cecil Medicine, p. 2485

STEP 2: Bone Marrow Study - MRD Testing (The Critical Checkpoint)

Think of this as: "Checking the battlefield after the attack"

After induction, a bone marrow sample is taken and tested for MRD = Minimal/Measurable Residual Disease.

MRD tells you: "Are there any cancer cells still hiding, even if we can't see them under a microscope?"

Techniques used: Flow cytometry or PCR - these can detect 1 cancer cell among 10,000 to 100,000 normal cells
MRD is the single most important predictor of whether the disease will relapse

Two possible results:

MRD Status	Meaning	Next step
Negative	Very few/no cancer cells remain	Standard (less intensive) path
Positive	Cancer cells are still detectable	More intensive (high-risk) path

PATH A: MRD Negative (Good response)

STEP 3A: Consolidation Phase (Another 2 cycles)

Think of this as: "Mop-up operations"

Goal: Kill any remaining microscopic cancer cells that survived induction
Uses different drugs than induction (to prevent resistance), including high-dose methotrexate, cytarabine, and cyclophosphamide
Given as short, intensive hospital-based courses
Goldman-Cecil Medicine describes most regimens as using 6 to 8 courses of consolidation in full protocols

STEP 4A: Maintenance Phase (2-3 years)

Think of this as: "Long-term guard duty"

Drugs used:

Methotrexate (weekly or bi-weekly, low dose)
6-Mercaptopurine (6-MP) (daily, oral)

Why so long?

ALL can hide in "sanctuary sites" (like the CNS or testes)
Low-dose long-term therapy prevents relapse without destroying the immune system completely
Duration: 2 to 3 years (standard; some protocols differ by sex - females may have shorter courses)

Important extra step not in the diagram: CNS (brain) prophylaxis. Without it, over 35% of ALL patients would develop brain relapse. It is given using:

Intrathecal (spinal) methotrexate/cytarabine injections
High-dose IV methotrexate (penetrates the blood-brain barrier)
(Cranial radiation is used less now due to long-term cognitive side effects)

PATH B: MRD Positive (Poor response / High-risk)

STEP 3B: 2 More Cycles of Intensive Chemotherapy

The patient has not responded well enough
More aggressive chemotherapy is given - sometimes using newer agents like blinatumomab (a bispecific antibody that recruits T-cells to kill leukemic blasts) or inotuzumab ozogamicin (a targeted antibody-drug conjugate)
The goal is to force the disease into MRD negativity before transplant

STEP 4B: Transplant (Stem Cell / Bone Marrow Transplant)

Think of this as: "Full system replacement"

An allogeneic stem cell transplant (allo-SCT) is performed - donor stem cells replace the patient's own bone marrow
The new immune system (from the donor) also attacks any remaining leukemia cells - this is called the Graft-versus-Leukemia (GvL) effect
This is the only potential cure for high-risk or MRD-positive ALL
High-risk features that also push toward transplant: Philadelphia chromosome (Ph+) ALL, poor cytogenetics, very high initial WBC count

Summary Diagram (Simple)

START: Diagnose ALL
         |
    [Induction x2 cycles]
    Steroids + Vincristine + Daunorubicin + Cyclophosphamide
         |
    [Bone Marrow MRD Test]
       /          \
   MRD -ve       MRD +ve
     |               |
Consolidation    2 more chemo cycles
  x2 cycles           |
     |            Transplant
Maintenance
(MTX + 6-MP)
  2-3 years

Key Facts to Remember

Point	Detail
Remission rate with induction	~90% in children, ~80-90% in adults
MRD negative = better prognosis	5-year survival >80% in children
MRD positive = high risk	Needs transplant for best outcome
Maintenance drugs	Methotrexate + 6-Mercaptopurine
Maintenance duration	2-3 years
CNS prophylaxis	Mandatory - prevents brain relapse
L-asparaginase removed because	Causes widespread thrombosis
Ph+ ALL (Philadelphia chromosome)	Needs TKI (e.g., Imatinib/Dasatinib) added to chemo

Goldman-Cecil Medicine (International Edition), p. 2480-2513

This is a shared conversation. Sign in to Orris to start your own chat.